

Emerging treatments for Leber Hereditary Optic Neuropathy and Retinitis Pigmentosa

Marta Zuccarelli, John-Joseph Borg, Janis Vella-Szijj, Anthony Serracino-Inglott

Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta email: marta.Zuccarelli.16@um.edu.mt

INTRODUCTION

Leber Hereditary Optic Neuropathy (LHON) and Retinitis Pigmentosa (RP) are rare-inherited diseases causing blindness with few treatments available within the European Union (EU). Raxone (idebenone) is the only approved medicinal product (MP) to treat LHON. Luxturna (voretigene neparvovec) is the only approved MP to


AIMS

Tounderstandemergingpatternspursuedbypharmaceuticalcompanieswhendevelopingmedicinalproducts to treat LHON and RP.

treat RP.

METHOD

Phase I: MPs for LHON and RP were identified from the EU CLINICAL TRIALS REGISTER and from the US NATIONAL LIBRARY OF MEDICINE DATABASE OF CLINICAL TRIALS. Prospective treatment protocols for LHON and RP were suggested based on mutationspecific MPs and mutation non-specific MPs. Phase II: Clinical development programs (CDPs) of MPs studied for LHON and RP were reviewed and analysed using descriptive statistics. Emerging patterns in primary endpoints studied between 2006 and 2018 were identified and compared Phase III: A review of available regulatory pathways within the EU to obtain a license for orphan MPs was carried out.



RESULTS

Nine MPs studied to treat LHON and 24 MPs to treat RP were analysed. Out of 9 MPs to treat LHON, 5 were included in the prospective treatment protocol. Out of 24 MPs to treat RP, 12 were included in the prospective treatment protocol.

The included MPs for LHON and for RP are shown in Table 1.

The most common endpoints studied in CTs were change in visual acuity (n=6) for LHON and change in visual field (n=8) for RP.

Raxone was authorised under exceptional circumstances for LHON in 2015 and protocol assistance was requested during its development. Luxturna was granted a full marketing

LHON	
Non-mutation specific	Mutation specific
Raxone®	GS010 (m.11778G>A)
Cysteamine bitartrate	
EPI-743	
Autologous-bone marrow stem cells	
RP	
Non-mutation specific	Mutation specific
Brimonideine Tartarte	Luxturna (RPE65)
Levodopa-Carbidopa	QLR091001 (RPE65)
Fluocinolone Acetonide	
jCell	CPK850 (RLBP1)
Bone marrow-derived	
mesenchymal stem cells	
Autologous bone marrow-	
derived mononuclear	Valproic Acid

authorisation for RP in 2018 after protocol assistance was requested twice during its development.

stem cells	(autosomal dominant
NT-501	RP)

Table 1 Medicinal products included in prospective treatment protocolsfor LHON (N=5) and RP (N=12)

CONCLUSION

An increased number of clinical trials associated with an increased number of drug classes explored between 2006 and 2018 have been noticed. New treatments specifically addressing mutated genes are being developed to treat LHON and RP. Only one MP for LHON and one MP for RP are currently available within the EU market and an unmet medical need is present.

Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta um.edu.mt/ms/pharmacy